Novo Nordisk: Initiating Buy, Calling The Bottom (NYSE:NVO)
· seekingalpha.com
Novo Nordisk's oral Wegovy is expanding the treated obesity market, not just cannibalizing injectables. Read why NVO stock is a Buy.
Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU ...